AsianScientist (Jan. 3, 2014) – Shenzhen Hepalink Pharmaceutical Co., Ltd. has entered into a stock purchase agreement to acquire Scientific Protein Laboratories, LLC, a manufacturer and supplier of active pharmaceutical ingredients (APIs).
With the acquisition, Hepalink will expand its presence as one of the leading suppliers of heparin worldwide, while providing the combined company with greater product development and growth opportunities in new markets for its full line of APIs, including pancreatic enzyme and heparin products.
“This represents an exciting opportunity for both companies and all of their employees in an increasingly global industry,” said Mr. Li Li, CEO of Hepalink. “After the acquisition, Hepalink will be able to further enhance the stability and safety of the supply of the heparin product raw materials, strengthen Hepalink’s globally leading advantages in technology, processing techniques, quality and safety standards, and form a global heparin API manufacturing, R&D and distribution network for Hepalink.”
Headquartered in Shenzhen, China, Hepalink is one of the world’s suppliers of processed heparin. It is also one of the select companies which have been approved to participate in the U.S. Pharmacopeial Convention’s Pharmaceutical Ingredient Verification Program, which includes rigorous testing, verification and certification of products intended for export to the United States.
“We are excited about this transaction and what it means for Scientific Protein Laboratories,” said Mr. Robert Mills, CEO of SPL. “This will expand our ability to develop and grow both our domestic and international businesses and to continue to conduct cutting-edge research on new products. We do not anticipate any changes in how we currently do business. We will become part of a very successful company that shares our commitment to safety and quality.”
——
Source: Shenzhen Hepalink Pharmaceutical Company.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
